<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFPROZIL
								 - cefprozil tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>CEFPROZIL TABLETS USP 250 mg and 500 mg<br>Rx only<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID107"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID109"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefprozil is a semi-synthetic broad-spectrum cephalosporin antibiotic.</p>
<p>Cefprozil is a cis and trans isomeric mixture (≥90% cis). The chemical name for the monohydrate is (6R,7R)-7-[(R)-2-amino-2-(p-hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2- carboxylic acid monohydrate, and the structural formula is:</p>
<div class="Figure"><img alt="Cefprozil USP" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75d57e35-ffeb-4d88-8dba-5458e284fd82&amp;name=cefprozil-tab-figure-01.jpg"></div>
<p>Cefprozil is a white to yellowish powder with a molecular formula for the monohydrate of C<span class="Sub">18</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S.H<span class="Sub">2</span>O and a molecular weight of 407.45.</p>
<p>Cefprozil tablets are intended for oral administration.</p>
<p>Cefprozil tablets contain cefprozil equivalent to 250 mg or 500 mg of anhydrous cefprozil. In addition, each tablet contains the following inactive ingredients: magnesium stearate, methylcellulose, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. The 250 mg tablet also contains FD &amp; C Yellow No. 6 Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID113"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The pharmacokinetic data were derived from the capsule formulation; however, bioequivalence has been demonstrated for the oral solution, capsule, tablet, and suspension formulations under fasting conditions.</p>
<p>Following oral administration of cefprozil to fasting subjects, approximately 95% of the dose was absorbed. The average plasma half-life in normal subjects was 1.3 hours, while the steady-state volume of distribution was estimated to be 0.23 L/kg. The total body clearance and renal clearance rates were approximately 3 mL/min/kg and 2.3 mL/min/kg, respectively.</p>
<p>Average peak plasma concentrations after administration of 250 mg, 500 mg, or 1 g doses of cefprozil to fasting subjects were approximately 6.1, 10.5, and 18.3 mcg/mL, respectively, and were obtained within 1.5 hours after dosing. Urinary recovery accounted for approximately 60% of the administered dose. (See Table.)</p>
<a name="ID115"></a><table width="100%">
<col width="28%">
<col width="14%">
<col width="10%">
<col width="10%">
<col width="38%">
<thead><tr class="First Last">
<td class="Lrule Rrule Toprule" align="center" colspan="1" valign="top">Dosage (mg) <br>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="3" valign="top">Mean Plasma Cefprozil <br>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" valign="top">8 hour Urinary Excretion (%) <br>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" colspan="1" valign="top"><br></td>
<td class="Lrule Rrule" align="center" colspan="3" valign="top">Concentrations (mcg/mL)
                              <br>
</td>
<td class="Lrule Rrule" align="center" colspan="1" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top">Peak appx. <br>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="1" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.5 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">250 mg <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.1 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.7 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.2 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">60% <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">500 mg <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10.5 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.2 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.4 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">62% <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1000 mg <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18.3 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8.4 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.0 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">54% <br>
</td>
</tr>
</tbody>
</table>
<p>During the first 4 hour period after drug administration, the average urine concentrations following 250 mg, 500 mg, and 1 g doses were approximately 700 mcg/mL, 1000 mcg/mL, and 2900 mcg/mL, respectively.</p>
<p>Administration of cefprozil with food did not affect the extent of absorption (AUC) or the peak plasma concentration (C<span class="Sub">max</span>) of cefprozil. However, there was an increase of 0.25 to 0.75 hours in the time to maximum plasma concentration of cefprozil (T<span class="Sub">max</span>).</p>
<p>The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.</p>
<p>Plasma protein binding is approximately 36% and is independent of concentration in the range of 2 mcg/mL to 20 mcg/mL.</p>
<p>There was no evidence of accumulation of cefprozil in the plasma in individuals with normal renal function following multiple oral doses of up to 1000 mg every 8 hours for 10 days.</p>
<p>In patients with reduced renal function, the plasma half-life may be prolonged up to 5.2 hours depending on the degree of the renal dysfunction. In patients with complete absence of renal function, the plasma half-life of cefprozil has been shown to be as long as 5.9 hours. The half-life is shortened during hemodialysis. Excretion pathways in patients with markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> have not been determined. (See <span class="Bold"><a href="#ID158">PRECAUTIONS</a></span>and <span class="Bold"><a href="#ID200">DOSAGE AND ADMINISTRATION</a>.)</span></p>
<p>In patients with impaired hepatic function, the half-life increases to approximately 2 hours. The magnitude of the changes does not warrant a dosage adjustment for patients with impaired hepatic function.</p>
<p>Healthy geriatric volunteers (≥65 years old) who received a single 1 g dose of cefprozil had 35% to 60% higher AUC and 40% lower renal clearance values compared with healthy adult volunteers 20 to 40 years of age. The average AUC in young and elderly female subjects was approximately 15% to 20% higher than in young and elderly male subjects. The magnitude of these age- and gender-related changes in the pharmacokinetics of cefprozil is not sufficient to necessitate dosage adjustments.</p>
<p>Adequate data on CSF levels of cefprozil are not available.</p>
<p>Comparable pharmacokinetic parameters of cefprozil are observed between pediatric patients (6 months to 12 years) and adults following oral administration of selected matched doses. The maximum concentrations are achieved at 1 to 2 hours after dosing. The plasma elimination half-life is approximately 1.5 hours. In general, the observed plasma concentrations of cefprozil in pediatric patients at the 7.5, 15, and 30 mg/kg doses are similar to those observed within the same time frame in normal adult subjects at the 250, 500, and 1000 mg doses, respectively. The comparative plasma concentrations of cefprozil in pediatric patients and adult subjects at the equivalent dose level are presented in the table below.</p>
<a name="ID117"></a><table width="99%">
<col width="19%">
<col width="18%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="14%">
<thead><tr class="First Last">
<td class="Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="center" colspan="5" valign="top">Mean (SD) Plasma Cefprozil <br>
</td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="7">
<p class="First"></p>
<p class="Footnote"><span class="Sup">a</span>n=11  <span class="Sup">b</span>n=5  <span class="Sup">c</span>n=9  <span class="Sup">d</span>n=11<br></p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top">Concentrations (mcg/mL) <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Population <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6 h <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">T½ (h) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">children <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">7.5 mg/kg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">4.70 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">3.99 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.91 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.23 <span class="Sup">a</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.94 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=18) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.57) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.24) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.30) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.13) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.32) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">adults <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">250 mg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">4.82 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">4.92 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.70<span class="Sup">b</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.53 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.28 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=12) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(2.13) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.13) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.53) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.17) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.34) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">children <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">15 mg/kg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">10.86 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">8.47 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2.75 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.61<span class="Sup">c</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.24 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=19) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(2.55) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(2.03) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.07) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.27) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.43) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">adults <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">500 mg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">8.39 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">9.42 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">3.18<span class="Sup">d</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.00<span class="Sup">d</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.29 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=12) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.95) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.98) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.76) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.24) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.14) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">children <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">30 mg/kg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">16.69 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">17.61 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">8.66 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">-- <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2.06 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=10) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(4.26) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(6.39) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(2.70) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.21) <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">adults <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1000 mg <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">11.99 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">16.95 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">8.36 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2.79 <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.27 <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">(n=12) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(4.67) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(4.07) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(4.13) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(1.77) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">(0.12) <br>
</td>
</tr>
</tbody>
</table>
<div class="Section">
<a name="ID118"></a><a name="section-3.1"></a><p></p>
<h2 class="Bold">Microbiology:</h2>
<p class="First">Cefprozil has <span class="Italics">in vitro </span>activity against a broad range of gram-positive and gram-negative bacteria. The bactericidal action of cefprozil results from inhibition of cell-wall synthesis. Cefprozil has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#ID139">INDICATIONS AND USAGE</a></span>section.</p>
<div class="Section">
<a name="ID120"></a><a name="section-3.1.1"></a><p></p>
<h3 class="Bold Italics">Aerobic Gram-Positive Microorganisms:</h3>
<p class="First"><span class="Italics">Staphylococcus aureus</span></p>
<p> (including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Bold">NOTE: </span>Cefprozil is inactive against methicillin-resistant staphylococci.</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
</div>
<div class="Section">
<a name="ID122"></a><a name="section-3.1.2"></a><p></p>
<h3 class="Bold Italics">Aerobic Gram-Negative Microorganisms:</h3>
<p class="First"><span class="Italics">Haemophilus influenzae</span></p>
<p> (including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p> (including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p>The following <span class="Italics">in vitro </span>data are available; however, their clinical significance is unknown. Cefprozil exhibits <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) of 8 mcg/mL or less against most (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of cefprozil in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section">
<a name="ID124"></a><a name="section-3.1.3"></a><p></p>
<h3 class="Bold Italics">Aerobic Gram-Positive Microorganisms:</h3>
<p class="First"><span class="Italics">Enterococcus durans</span></p>
<p><span class="Italics">Enterococcus faecalis</span></p>
<p><span class="Italics">Listeria monocytogenes</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span></p>
<p><span class="Italics">Staphylococcus saprophyticus</span></p>
<p><span class="Italics">Staphylococcus warneri</span></p>
<p><span class="Italics">Streptococcus agalactiae</span></p>
<p>Streptococci (Groups C, D, F, and G)</p>
<p>viridans group Streptococci</p>
<p><span class="Bold">NOTE: </span>Cefprozil is inactive against <span class="Italics">Enterococcus faecium </span>.</p>
</div>
<div class="Section">
<a name="ID126"></a><a name="section-3.1.4"></a><p></p>
<h3 class="Bold Italics">Aerobic Gram-Negative Microorganisms:</h3>
<p class="First"><span class="Italics">Citrobacter diversus</span></p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<p> (including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>spp<span class="Italics">.</span></p>
<p><span class="Italics">Shigella </span>spp .</p>
<p><span class="Italics">Vibrio </span>spp.</p>
<p><span class="Bold">NOTE: </span>Cefprozil is inactive against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia, Pseudomonas</span>, and <span class="Italics">Serratia.</span></p>
</div>
<div class="Section">
<a name="ID128"></a><a name="section-3.1.5"></a><p></p>
<h3 class="Bold Italics">Anaerobic Microorganisms:</h3>
<p class="First"><span class="Italics">Prevotella (Bacteroides) melaninogenicus</span></p>
<p><span class="Italics">Clostridium difficile</span></p>
<p><span class="Italics">Clostridium perfringens</span></p>
<p><span class="Italics">Fusobacterium </span>spp.</p>
<p><span class="Italics">Peptostreptococcus </span>spp<span class="Italics">.</span></p>
<p><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Bold">NOTE: </span>Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the <span class="Italics">Bacteroides fragilis </span>group are resistant to cefprozil.</p>
</div>
<div class="Section">
<a name="ID130"></a><a name="section-3.1.6"></a><p></p>
<h3 class="Bold Italics">Susceptibility Tests:</h3>
<p class="First"><span class="Bold Italics Underline">Dilution Techniques: </span>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1,2</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefprozil powder. The MIC values should be interpreted according to the following criteria:</p>
<a name="ID132"></a><table width="100%">
<col width="39%">
<col width="61%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">MIC </span><span class="Bold Underline">(</span><span class="Bold Underline">mcg</span><span class="Bold Underline">/</span><span class="Bold Underline">mL</span><span class="Bold Underline">) </span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">Interpretation </span><span class="Bold Underline"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤8 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">          Susceptible          (S) <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">         Intermediate         (I) <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥32 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">          Resistant             (R) <br>
</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard cefprozil powder should provide the following MIC values:</p>
<a name="ID134"></a><table width="100%">
<col width="72%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">   </span><span class="Bold Underline">Microorganism</span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">MIC </span><span class="Bold Underline">(</span><span class="Bold Underline">mcg</span><span class="Bold Underline">/</span><span class="Bold Underline">mL</span><span class="Bold Underline">) </span><span class="Bold Underline"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">        Enterococcus faecalis ATCC 29212 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4-16 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">        Escherichia coli ATCC 25922 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1-4 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">        Haemophilus influenzae ATCC 49766 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1-4 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">        Staphylococcus aureus ATCC 29213 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.25-1 <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">        Streptococcus pneumoniae ATCC 49619 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.25-1 <br>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics Underline">Diffusion Techniques: </span>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg cefprozil to test the susceptibility of microorganisms to cefprozil.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg cefprozil disk should be interpreted according to the following criteria:</p>
<a name="ID136"></a><table width="100%">
<col width="45%">
<col width="55%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">Zone </span><span class="Bold Underline">diameter </span><span class="Bold Underline">(</span><span class="Bold Underline">mm</span><span class="Bold Underline">) </span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">Interpretation </span><span class="Bold Underline"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥18 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">          Susceptible          (S) <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15-17 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">        Intermediate          (I) <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤14 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">           Resistant             (R) <br>
</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefprozil.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg cefprozil disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<a name="ID138"></a><table width="100%">
<col width="67%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">          <span class="Bold Underline">Microorganism </span><span class="Bold Underline"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold Underline">Zone </span><span class="Bold Underline">diameter </span><span class="Bold Underline">(</span><span class="Bold Underline">mm</span><span class="Bold Underline">) </span><span class="Bold Underline"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">          Escherichia coli ATCC 25922 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21-27 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">          Haemophilus influenzae ATCC 49766 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20-27 <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">          Staphylococcus aureus ATCC 25923 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">27-33 <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">          Streptococcus pneumoniae ATCC 49619 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25-32 <br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID139"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cefprozil tablets are indicated for the treatment of patients with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below:</p>
<div class="Section">
<a name="ID141"></a><a name="section-4.1"></a><p></p>
<h2 class="Bold">Upper Respiratory Tract:</h2>
<div class="Section">
<a name="ID142"></a><a name="section-4.1.1"></a><p></p>
<h3 class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span>:</h3>
<p class="First">Caused by <span class="Italics">Streptococcus pyogenes</span>.</p>
<p>NOTE: The usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of <span class="Italics">Streptococcus pyogenes </span>from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available at present. </p>
</div>
<div class="Section">
<a name="ID144"></a><a name="section-4.1.2"></a><p></p>
<h3 class="Bold Italics"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>:</h3>
<p class="First">Caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae </span>(including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), and <span class="Italics">Moraxella (Branhamella) catarrhalis </span>(including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>). (See <span class="Bold"><a href="#ID210">CLINICAL STUDIES</a>.)</span></p>
<p>NOTE: In the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors.</p>
</div>
<div class="Section">
<a name="ID146"></a><a name="section-4.1.3"></a><p></p>
<h3 class="Bold Italics"><span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">Acute Sinusitis</span>:</h3>
<p class="First">Caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae </span>(including ß-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), and <span class="Italics">Moraxella (Branhamella) catarrhalis </span>(including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
</div>
</div>
<div class="Section">
<a name="ID148"></a><a name="section-4.2"></a><p></p>
<h2 class="Bold">Lower Respiratory Tract:</h2>
<div class="Section">
<a name="ID149"></a><a name="section-4.2.1"></a><p></p>
<h3 class="Bold Italics">Secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infection</span> of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Acute Bronchitis</span> and <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span>:</h3>
<p class="First">Caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae </span>(including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), and <span class="Italics">Moraxella (Branhamella) catarrhalis </span>(including ß-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
</div>
</div>
<div class="Section">
<a name="ID151"></a><a name="section-4.3"></a><p></p>
<h2 class="Bold">Skin and Skin Structure:</h2>
<div class="Section">
<a name="ID152"></a><a name="section-4.3.1"></a><p></p>
<h3 class="Bold Italics">Uncomplicated Skin and Skin-Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</h3>
<p class="First">Caused by <span class="Italics">Staphylococcus aureus </span>(including penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) and <span class="Italics">Streptococcus pyogenes</span>. <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> usually require surgical drainage.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID154"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefprozil is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin class of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID156"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH CEFPROZIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFPROZIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG ß-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFPROZIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Cefprozil, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD.                        Hypertoxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID158"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="ID159"></a><a name="section-7.1"></a><p></p>
<h2 class="Bold">General:</h2>
<p class="First">Prescribing cefprozil in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.</p>
<p>In patients with known or suspected <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#ID200">DOSAGE AND ADMINISTRATION</a>),</span>careful clinical observation and appropriate laboratory studies should be done prior to and during therapy. The total daily dose of cefprozil should be reduced in these patients because high and/or prolonged plasma antibiotic concentrations can occur in such individuals from usual doses. Cephalosporins, including cefprozil, should be given with caution to patients receiving concurrent treatment with potent diuretics since these agents are suspected of adversely affecting renal function.</p>
<p>Prolonged use of cefprozil may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken. </p>
<p>Cefprozil should be prescribed with caution in individuals with a history of gastrointestinal disease particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Positive direct Coombs’ tests have been reported during treatment with cephalosporin antibiotics.</p>
</div>
<div class="Section">
<a name="ID161"></a><a name="section-7.2"></a><p></p>
<h2 class="Bold">Information for Patients:</h2>
<p class="First">Patients should be counseled that antibacterial drugs including cefprozil should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefprozil are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefprozil or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section">
<a name="ID163"></a><a name="section-7.3"></a><p></p>
<h2 class="Bold">Drug Interactions:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil.</p>
<p>The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.</p>
</div>
<div class="Section">
<a name="ID165"></a><a name="section-7.4"></a><p></p>
<h2 class="Bold">Drug/Laboratory Test Interactions:</h2>
<p class="First">Cephalosporin antibiotics may produce a false positive reaction for glucose in the urine with copper reduction tests (Benedict’s or Fehling’s solution or with Clinitest<span class="Sup">®</span> tablets), but not with enzyme-based tests for <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> (e.g., Clinistix<span class="Sup">®</span>). A false negative reaction may occur in the ferricyanide test for blood glucose. The presence of cefprozil in the blood does not interfere with the assay of plasma or urine creatinine by the alkaline picrate method.</p>
</div>
<div class="Section">
<a name="ID167"></a><a name="section-7.5"></a><p></p>
<h2 class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long term <span class="Italics">in vivo </span>studies have not been performed to evaluate the carcinogenic potential of cefprozil.</p>
<p>Cefprozil was not found to be mutagenic in either the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>or <span class="Italics">E. coli </span>WP2 urvA reversion assays or the Chinese hamster ovary cell HGPRT forward gene mutation assay and it did not induce chromosomal abnormalities in Chinese hamster ovary cells or unscheduled DNA synthesis in rat hepatocytes <span class="Italics">in vitro</span>. Chromosomal aberrations were not observed in bone marrow cells from rats dosed orally with over 30 times the highest recommended human dose based upon mg/m<span class="Sup">2</span>.</p>
<p>Impairment of fertility was not observed in male or female rats given oral doses of cefprozil up to 18.5 times the highest recommended human dose based upon mg/m<span class="Sup">2</span>.</p>
</div>
<div class="Section">
<a name="ID169"></a><a name="section-7.6"></a><p></p>
<h2 class="Bold">Pregnancy:</h2>
<div class="Section">
<a name="ID170"></a><a name="section-7.6.1"></a><p></p>
<h3 class="Bold Italics">Teratogenic Effects- Pregnancy Category B:</h3>
<p class="First">Reproduction studies have been performed in rabbits, mice, and rats using oral doses of cefprozil of 0.8, 8.5, and 18.5 times the maximum daily human dose (1000 mg) based upon mg/m<span class="Sup">2</span>, and have revealed no harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section">
<a name="ID172"></a><a name="section-7.7"></a><p></p>
<h2 class="Bold">Labor and Delivery:</h2>
<p class="First">Cefprozil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</p>
</div>
<div class="Section">
<a name="ID174"></a><a name="section-7.8"></a><p></p>
<h2 class="Bold">Nursing Mothers:</h2>
<p class="First">Small amounts of cefprozil (&lt;0.3% of dose) have been detected in human milk following administration of a single 1 gram dose to lactating women. The average levels over 24 hours ranged from 0.25 to 3.3 mcg/mL. Caution should be exercised when cefprozil tablets are administered to a nursing woman, since the effect of cefprozil on nursing infants is unknown.</p>
</div>
<div class="Section">
<a name="ID176"></a><a name="section-7.9"></a><p></p>
<h2 class="Bold">Pediatric Use:</h2>
<p class="First">(See <span class="Bold"><a href="#ID139">INDICATIONS AND USAGE</a></span>and <span class="Bold"><a href="#ID200">DOSAGE AND ADMINISTRATION</a>.)</span></p>
<p>The safety and effectiveness of cefprozil in the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> have been established in the age groups 6 months to 12 years. Use of cefprozil for the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is supported by evidence from adequate and well-controlled studies of cefprozil in pediatric patients. (See <span class="Bold"><a href="#ID210">CLINICAL STUDIES</a>)</span></p>
<p>The safety and effectiveness of cefprozil in the treatment of <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or uncomplicated skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> have been established in the age groups 2 to 12 years. Use of cefprozil for the treatment of these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is supported by evidence from adequate and well-controlled studies of cefprozil in pediatric patients.</p>
<p>The safety and effectiveness of cefprozil in the treatment of <span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">acute sinusitis</span> have been established in the age groups 6 months to 12 years. Use of cefprozil in these age groups is supported by evidence from adequate and well-controlled studies of cefprozil in adults.</p>
<p>Safety and effectiveness in pediatric patients below the age of 6 months have not been established for the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> or <span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">acute sinusitis</span>, or below the age of 2 years for the treatment of <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or uncomplicated skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. However, accumulation of other cephalosporin antibiotics in newborn infants (resulting from prolonged drug half-life in this age group) has been reported.</p>
</div>
<div class="Section">
<a name="ID178"></a><a name="section-7.10"></a><p></p>
<h2 class="Bold">Geriatric Use:</h2>
<p class="First">Of the more than 4500 adults treated with cefprozil in clinical studies, 14% were 65 years and older, while 5% were 75 years and older. When geriatric patients received the usual recommended adult doses, their clinical efficacy and safety were comparable to clinical efficacy and safety in nongeriatric adult patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals to the effects of cefprozil cannot be excluded (see <span class="Bold"><a href="#ID113">CLINICAL PHARMACOLOGY</a>).</span></p>
<p>Cefprozil is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. See <span class="Bold"><a href="#ID200">DOSAGE AND ADMINISTRATION </a></span>for dosing recommendations for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID180"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. Cefprozil was usually well tolerated in controlled clinical trials. Approximately 2% of patients discontinued cefprozil therapy due to adverse events.</p>
<p>The most common adverse effects observed in patients treated with cefprozil are:</p>
<div class="Section">
<a name="ID182"></a><a name="section-8.1"></a><p></p>
<h2 class="Bold">Gastrointestinal:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (2.9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3.5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1%).</p>
</div>
<div class="Section">
<a name="ID184"></a><a name="section-8.2"></a><p></p>
<h2 class="Bold">Hepatobiliary:</h2>
<p class="First">Elevations of AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (2%), ALT (SGPT) (2%), alkaline phosphatase (0.2%), and bilirubin values (&lt;0.1%). As with some penicillins and some other cephalosporin antibiotics, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> has been reported rarely.</p>
</div>
<div class="Section">
<a name="ID186"></a><a name="section-8.3"></a><p></p>
<h2 class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (0.9%), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (0.1%). Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy.</p>
</div>
<div class="Section">
<a name="ID188"></a><a name="section-8.4"></a><p></p>
<h2 class="Bold">CNS:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (1%). <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported rarely (&lt;1%). All were reversible.</p>
</div>
<div class="Section">
<a name="ID190"></a><a name="section-8.5"></a><p></p>
<h2 class="Bold">Hematopoietic:</h2>
<p class="First">Decreased leukocyte count (0.2%), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> (2.3%).</p>
</div>
<div class="Section">
<a name="ID192"></a><a name="section-8.6"></a><p></p>
<h2 class="Bold">Renal:</h2>
<p class="First">Elevated BUN (0.1%), serum creatinine (0.1%).</p>
</div>
<div class="Section">
<a name="ID194"></a><a name="section-8.7"></a><p></p>
<h2 class="Bold">Other:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">Diaper rash</span> and <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> (1.5%), <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span> and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1.6%).</p>
<p>The following adverse events, regardless of established causal relationship to cefprozil tablets, have been rarely reported during postmarketing surveillance: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>), <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, serum-sickness like reactions, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section">
<a name="ID196"></a><a name="section-8.8"></a><p></p>
<h2 class="Bold">Cephalosporin Class Paragraph:</h2>
<p class="First">In addition to the adverse reactions listed above which have been observed in patients treated with cefprozil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:</p>
<p><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, positive Coombs’ test, elevated LDH, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, when the dosage was not reduced. (See<a href="#ID200"> DOSAGE AND ADMINISTRATION</a> and <span class="Bold"><a href="#ID198">OVERDOSAGE</a>.)</span>If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID198"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weanling, or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and loss of appetite in cynomolgus monkeys, but no mortality.</p>
<p>Cefprozil is eliminated primarily by the kidneys. In case of severe overdosage, especially in patients with compromised renal function, hemodialysis will aid in the removal of cefprozil from the body.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID200"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Cefprozil tablets are administered orally.</p>
<a name="ID202"></a><table width="99%">
<col width="70%">
<col width="19%">
<col width="10%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">Population/Infection <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">Dosage (mg) <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">Duration (days) <br>
</td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
<p class="First"></p>
<p class="Footnote"><span class="Sup">a</span> In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to Streptococcus pyogenes, cefprozil tablets should be administered for at least 10 days.<br></p>
<p class="Footnote"><span class="Sup">b</span> Not to exceed recommended adult doses.<br></p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"> ADULTS (13 years and older)  <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    UPPER RESPIRATORY TRACT <br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">         <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/Tonsillitis <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">500 q24h <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <span class="Sup">a</span><br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">         Acute Sinusitis <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">250 q12h or <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">         (For moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the higher dose should be used) <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">500 q12h <br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    LOWER RESPIRATORY TRACT <br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">         Secondary Bacterial Infection of Acute Bronchitis and <br>        Acute Bacterial Exacerbation of Chronic Bronchitis <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">500 q12h <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    SKIN AND SKIN STRUCTURE <br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">         Uncomplicated Skin and Skin Structure Infections <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">250 q12h or <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top">500 q24h or <br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">500 q12h <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"> CHILDREN (2 years-12 years) <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    UPPER RESPIRATORY TRACT <span class="Sup">b</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">        <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/Tonsillitis <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">7.5 mg/kg q12h <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <span class="Sup">a</span><br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    SKIN AND SKIN STRUCTURE<span class="Sup">b</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">        Uncomplicated Skin and Skin Structure Infections <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">20 mg/kg q24h <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"> INFANTS &amp; CHILDREN (6 months-12 years) <br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">    UPPER RESPIRATORY TRACT<span class="Sup">b</span><br>
</td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">        Otitis Media <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">15 mg/kg q12h <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">        (See <a href="#ID139">INDICATIONS AND USAGE</a> and <a href="#ID210">CLINICAL STUDIES</a>)  </td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
<td class="Lrule Rrule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">        Acute Sinusitis <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">7.5 mg/kg q12h or <br>
</td>
<td class="Lrule Rrule" align="center" valign="top">10 <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">        (For moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the higher dose should be used) <br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">15 mg/kg q12h <br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="top"><br></td>
</tr>
</tbody>
</table>
<div class="Section">
<a name="ID203"></a><a name="section-10.1"></a><p></p>
<h2 class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</h2>
<p class="First">Cefprozil may be administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. The following dosage schedule should be used.</p>
<a name="ID205"></a><table width="101%">
<col width="55%">
<col width="23%">
<col width="23%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Creatinine </span><span class="Bold">Clearance </span><span class="Bold">(</span><span class="Bold">mL</span><span class="Bold">/</span><span class="Bold">min</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Dosage </span><span class="Bold">(</span><span class="Bold">mg</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Dosing </span><span class="Bold">Interval </span><span class="Bold"><br></span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30-120 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">standard <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">standard <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0-29<span class="Sup"> </span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50% of standard <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">standard <br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID206"></a><a name="section-10.2"></a><p></p>
<h2 class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</h2>
<p class="First">No dosage adjustment is necessary for patients with impaired hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID208"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each white film-coated, oval tablet debossed with ‘LUPIN’ on one side and ‘500’ on the other side, contains the equivalent of 500 mg anhydrous cefprozil.</p>
<p>Bottles of 20 Tablets                         NDC 54868-5756-0<br></p>
<p><br></p>
<p>Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID210"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section">
<a name="ID211"></a><a name="section-12.1"></a><p></p>
<h2 class="Bold">Study One:</h2>
<p class="First">In a controlled clinical study of <span class="Bold">acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> </span>performed in the United States where significant rates of ß-lactamase- producing organisms were found, cefprozil was compared to an oral antimicrobial agent that contained a specific ß-lactamase inhibitor. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 10-16 days post-therapy follow-up, the following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) and safety results were obtained:</p>
<p>                                                                         <span class="Bold Underline">U.S. Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> Study</span></p>
<p>                                                  <span class="Bold Underline">Cefprozil vs β-lactamase inhibitor-containing control drug</span></p>
<p><span class="Italics">EFFICACY:</span></p>
<a name="ID213"></a><table width="99%">
<col width="18%">
<col width="32%">
<col width="49%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Pathogen</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Cases </span><span class="Bold">with </span><span class="Bold">Pathogen</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">n</span><span class="Bold">=</span><span class="Bold">155</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Outcome</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">pneumoniae</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">48.4%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil success rate 5% better than control<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">H</span><span class="Italics">. </span><span class="Italics">influenzae</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35.5%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil success rate 17% less than control<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">M</span><span class="Italics">. </span><span class="Italics">catarrhalis</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13.5%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil success rate 12% less than control<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">pyogenes</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.6%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Overall</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">100.0%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil success rate 5% less than control<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">SAFETY:</span></p>
<p>The incidences of adverse events, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span><span class="Sup">*</span>, were clinically and statistically significantly higher in the control arm versus the cefprozil arm.</p>
<a name="ID215"></a><table width="100%">
<col width="46%">
<col width="29%">
<col width="25%">
<tfoot><tr class="First Last"><td align="left" colspan="3">
<p class="First"></p>
<p class="Footnote"><span class="Sup">*</span><span class="Sup"></span>The majority of these involved the diaper area in young children.<br></p>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Age </span><span class="Bold">Group</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cefprozil</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Control</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6 months-2 years<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">41%<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3-12 years<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19%<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID216"></a><a name="section-12.2"></a><p></p>
<h2 class="Bold">Study Two:</h2>
<p class="First">In a controlled clinical study of <span class="Bold">acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> </span>performed in Europe, cefprozil was compared to an oral antimicrobial agent that contained a specific ß-lactamase inhibitor. As expected in a European population, this study population had a lower incidence of ß-lactamase-producing organisms than usually seen in U.S. trials. In this study, using very strict evaluability criteria and microbiologic and clinical response criteria at the 10-16 days post-therapy follow-up, the following presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) were obtained:</p>
<p>                                                                 <span class="Bold Underline">European Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> Study</span></p>
<p>                                          <span class="Bold Underline">Cefprozil vs β-lactamase inhibitor-containing control drug</span></p>
<p><span class="Italics">EFFICACY:</span></p>
<a name="ID218"></a><table width="99%">
<col width="19%">
<col width="43%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Pathogen </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Cases </span><span class="Bold">with </span><span class="Bold">Pathogen </span><span class="Bold">(</span><span class="Bold">n</span><span class="Bold">=</span><span class="Bold">47</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Outcome </span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">pneumoniae </span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">51.0% <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">H</span><span class="Italics">. </span><span class="Italics">influenzae </span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">29.8% <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">M</span><span class="Italics">. </span><span class="Italics">catarrhalis </span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.4% <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control <br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">pyogenes </span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12.8% <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Overall </span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">100.0% <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">cefprozil equivalent to control <br>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">SAFETY:</span></p>
<p>The incidence of adverse events in the cefprozil arm was comparable to the incidence of adverse events in the control arm (agent that contained a specific ß-lactamase inhibitor).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID220"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>-Third Edition. Approved Standard NCCLS Document M7-A3, Vol.13, No. 25, NCCLS, Villanova, PA, December 1993.</li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria</span>-Third Edition. Approved Standard NCCLS Document M11-A3, Vol. 13, No. 26, NCCLS, Villanova, PA, December 1993.</li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests </span>-Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993.</li>
</ol>
<p class="First">Clintest<span class="Sup">®</span> and Clinistix<span class="Sup">®</span> are registered trademarks of Bayer HealthCare LLC.</p>
<p>Manufactured for:                                                                         Manufactured by                      </p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.                                       Lupin Limited</span></p>
<p>Baltimore, Maryland 21202                                                         Mumbai 400 098</p>
<p>United States                                                                                INDIA</p>
<p>Revised: December, 2007                                                          ID#: 213043</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID223"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<br><p class="First">CEFPROZIL TABLETS USP</p>
<p>Rx Only</p>
<p>500 mg</p>
<div class="Figure"><img alt="image of 500 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75d57e35-ffeb-4d88-8dba-5458e284fd82&amp;name=5756.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFPROZIL
								 		
					</strong><br><span class="contentTableReg">cefprozil tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5756(NDC:68180-404)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFPROZIL</strong> (CEFPROZIL ANHYDROUS) </td>
<td class="formItem">CEFPROZIL ANHYDROUS</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLCELLULOSE (15 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LUPIN;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5756-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065276</td>
<td class="formItem">02/05/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f0ec7dd9-476e-4705-a48f-ea90942be3fd</div>
<div>Set id: 75d57e35-ffeb-4d88-8dba-5458e284fd82</div>
<div>Version: 1</div>
<div>Effective Time: 20120507</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
